Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
 - EconoTimes)
NEW ORLEANS, La., March 10, 2017 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 27, 2017 to file lead plaintiff applications in a securities class action lawsuit against Mallinckrodt Public Limited Company (NYSE:MNK), if they purchased the Company’s securities between November 25, 2014 and January 18, 2017, inclusive (the “Class Period”). The action is pending in United States District Court for the District of Columbia.
What You May Do
If you purchased securities of Mallinckrodt and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 27, 2017.
About the Lawsuit
The complaint alleges that, throughout the Class Period, Mallinckrodt and its CEO, Mark Trudeau, made a series of false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of Mallinckrodt’s revenues for HP Acthar Gel (“Acthar”), the only FDA-approved adrenocorticotropic hormone preparation. The action alleges that Acthar’s monopoly status was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
